[Etiology, therapy and prognosis of chronic hepatitis].
The therapy and prognosis of chronic active hepatitis (CAH) depends upon the morphology (stage and activity of the liver process) and etiology. In our own long-term study (n = 167), HBV-markers were found in 72% of cases, and an additional 14% belonged to the non-B/non-autoimmune type. For neither form is an established therapy available. Interestingly, 50% of cases with autoimmune CAH had HBV markers. Steroid therapy seems to be beneficial only in cases with very active autoimmune CAH. The mortality in our series was around 50% for the HBV-type (with B-persistence) and for autoimmune CAH. In the HBV-type (with B-loss) and in the non-B/non-autoimmune type the mortality was around 15%.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000628:therapy; D056486:Chemical and Drug Induced Liver Injury / Q000628:therapy; D003131:Combined Modality Therapy; D006509:Hepatitis B / Q000628:therapy; D006526:Hepatitis C / Q000628:therapy; D006521:Hepatitis, Chronic / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008111:Liver Function Tests; D011379:Prognosis
D000305:Adrenal Cortex Hormones
Atiologie, Therapie und Prognose der chronischen Hepatitis.